Pharma News

Strides Shasun acquires Australian and Kenyan generics makers

Home/Pharma News | Posted 18/03/2016

India-based generics manufacturer Strides Shasun has increased its generics portfolio and presence across the globe with two new acquisitions.

Mylan to acquire Swedish drugmaker Meda

Home/Pharma News | Posted 04/03/2016

US generics manufacturer Mylan announced on 10 February 2016 that it had made a deal worth US$9.9 billion (for shares and debt) to buy Swedish drugmaker Meda.

Fuji Pharma gains rights to darbepoetin alfa biosimilar in Japan

Home/Pharma News | Posted 12/02/2016

Japan-based Fuji Pharma announced on 5 January 2016 that it had signed a license agreement with Chong Kun Dang Pharmaceutical (CKD Pharma). Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribution and sale of CKD Pharma’s darbepoetin alfa biosimilar (CKD‑11101).

Mylan and Momenta to jointly develop and commercialize six biosimilar products

Home/Pharma News | Posted 05/02/2016

Mylan NV has agreed an exclusive global collaboration with Momenta Pharmaceuticals Inc (Momenta) to develop, manufacture and commercialize six of Momenta's biosimilar candidates.

Eisai acquires Chinese generics maker

Home/Pharma News | Posted 22/01/2016

Japanese pharmaceutical company Eisai announced on 28 December 2015 that it had acquired Chinese generics maker Liaoning TianYi Biological Pharmaceutical.

Teva and Takeda partner for generics in Japan

Home/Pharma News | Posted 11/12/2015

Israeli generics giant Teva Pharmaceutical Industries (Teva) and Japan-based Takeda Pharmaceutical (Takeda) announced on 30 November 2015 that they had made a partnership to provide generics in Japan.

Generic injectable prices stay high even after shortages resolved

Home/Pharma News | Posted 27/11/2015

Hospitals that have been struggling with shortages and subsequent high prices are now complaining that even after supply gets back to normal prices remain high.

Mylan will not be acquiring Perrigo

Home/Pharma News | Posted 20/11/2015

Generics company Mylan has failed in its lengthy multi-billion dollar hostile bid to acquire competing generics company Perrigo.

Pfizer cuts some biosimilars after Hospira deal

Home/Pharma News | Posted 13/11/2015

After completing its US$17 billion acquisition of Hospira, Pfizer is cutting some of its biosimilar collaborations with South Korean drugmaker Celltrion.

Merck Millipore to collaborate with Turkish firm on biosimilars

Home/Pharma News | Posted 06/11/2015

The Life Science division of Merck, Merck Millipore and Turkish biosimilars start-up Turgut Ilaç are to collaborate on biosimilars.

Teva acquires Mexican drugmaker Rimsa

Home/Pharma News | Posted 16/10/2015

Israeli generics giant Teva Pharmaceutical Industries (Teva) is expanding its presence in emerging markets with its acquisition of Mexico-based Representaciones e Investigaciones Medicas SA de CV (Rimsa), a specialty drugmaker with a portfolio of products and patents across Latin America.

Mylan goes after Perrigo

Home/Pharma News | Posted 09/10/2015

US generics manufacturer Mylan announced on 14 September 2015 that it had officially commenced its formal offer to acquire all outstanding ordinary shares of rival Ireland-based generics maker Perrigo Company (Perrigo).

Epirus expands biosimilars pipeline with Bioceros acquisition

Home/Pharma News | Posted 02/10/2015

US-based Epirus Biopharmaceuticals (Epirus) announced on 9 September 2015 that it has acquired Netherlands-based biopharmaceutical company Bioceros Holding (Bioceros).

UCB sells generics unit to Lannett

Home/Pharma News | Posted 11/09/2015

Belgium-based biopharmaceutical company UCB announced on 2 September 2015 that it would sell its US specialty generics business, Kremers Urban, to US generics company Lannett for US$1.23 billion in cash plus contingent payments.

US FTC clears Pfizer’s purchase of Hospira

Home/Pharma News | Posted 04/09/2015

Pharma giant Pfizer announced on 24 August 2015 that the US Federal Trade Commission (FTC) terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of US-based injectable generics specialist and biosimilars maker Hospira.

ANI Pharma and IDT Australia collaborate on US generics

Home/Pharma News | Posted 28/08/2015

US-based brand-name and generic drugmaker ANI Pharmaceuticals (ANI) announced on 12 August 2015 that it had entered into a collaboration with generics company IDT Australia (IDT) to commercialize up to 18 previously marketed US generics.

Mergers between Watson/Actavis and ANI Pharma/BioSante

Home/Pharma News | Posted 19/10/2012

Mergers are once again on the agenda as companies strive to meet the constant demands of governments to cut costs and yet still make a profit.

AstraZeneca and Fujifilm Kyowa Kirin Biologics to collaborate on bevacizumab biosimilar

Home/Pharma News | Posted 21/08/2015

Japanese biosimilars maker Fujifilm Kyowa Kirin Biologics announced on 24 July 2015 that it had entered into an agreement with pharma giant AstraZeneca to establish a joint venture for the development and commercialization of its candidate biosimilar, FKB238.

Hikma to acquire Boehringer Ingelheim’s US generics business

Home/Pharma News | Posted 21/08/2015

Jordan-based drugmaker Hikma Pharmaceuticals (Hikma) announced on 28 July 2015 that it had made a deal with Germany’s Boehringer Ingelheim to acquire the latter’s US generics business: Roxane Laboratories and Boehringer Ingelheim Roxane (Roxane).

Lupin to expand US generics business with Gavis acquisition

Home/Pharma News | Posted 07/08/2015

Indian generics manufacturer Lupin Pharmaceuticals (Lupin) announced on 23 July 2015 that it had entered into a definitive agreement to acquire US generics makers Gavis Pharmaceuticals and Novel Laboratories (Gavis).

Acquisitions for Endo and Strides

Home/Pharma News | Posted 26/06/2015

Endo Pharmaceuticals (Endo) and Strides Arcolab (Strides) are both looking at acquisitions as a way to expand their generics businesses.

Amneal to acquire Australian generics business from Actavis

Home/Pharma News | Posted 15/05/2015

Privately held US generics maker Amneal Pharmaceuticals (Amneal) announced on 31 March 2015 that it had made a deal with the Australian subsidiary of Actavis to acquire the Australian generics business of Actavis for an undisclosed amount.

Anticompetitive acquisition forces generics sale

Home/Pharma News | Posted 08/05/2015

US generics maker CorePharma has had to sell its rights of two generics in order to merge with fellow US drug company Impax Laboratories (Impax). The US Federal Trade Commission (FTC) ruled that Impax’s acquisition of CorePharma would have been anticompetitive unless CorePharma sold its rights and assets for pilocarpine, a drug used to treat dry mouth and glaucoma, and ursodiol, a treatment for liver and gall bladder diseases.

Teva finally makes bid for Mylan

Home/Pharma News | Posted 04/05/2015

In the wake of many rumours, Israeli generics giant Teva Pharmaceutical Industries (Teva) finally announced on 21 April 2015 that it had made a bid for US-based generics maker Mylan.

Growing investment in Vietnam

Home/Pharma News | Posted 27/04/2015

Cyprus-based generics company Medochemie is building its second factory in Vietnam. Construction on the site, which will occupy 44,700 square metres, is expected to be completed by the end of 2015 with operations commencing in early 2016.

Teva to buy Auspex Pharma, reinforcing CNS portfolio

Home/Pharma News | Posted 10/04/2015

Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 30 March 2015 that it would buy US biopharmaceutical company Auspex Pharmaceuticals (Auspex) for an equity value of US$3.5 billion.

India to set up pharma manufacturing clusters

Home/Pharma News | Posted 03/04/2015

The Indian Government is planning to set up pharmaceutical manufacturing clusters in order to reduce costs and make the industry more competitive.

Boehringer Ingelheim loses patent battle with India’s Cipla

Home/Pharma News | Posted 20/03/2015

German pharmaceutical company Boehringer Ingelheim (Boehringer) has lost its patent on the Spiriva respiratory drug in India. The Indian patent office has agreed with the Indian drugmaker Cipla that Boehringer’s Spiriva patent was obvious and was not an invention under India’s patent laws.

Indian Government to launch own brand of generics

Home/Pharma News | Posted 06/03/2015

Not happy with its current control over the price of drugs in the country, the Indian Government has announced plans to launch its own brand of low cost generics.

Canada clamps down on companies failing to post drug shortage information

Home/Pharma News | Posted 27/02/2015

The Canadian Government has made it mandatory for drug companies to report actual and anticipated drug shortages. A voluntary system that had been in place was not working well enough, said the country’s Health Minister, Rona Ambrose.

Pfizer sets to lead biosimilars and generics markets

Home/Pharma News | Posted 20/02/2015

Pharma giant Pfizer has announced it is to buy injectable generics specialist and biosimilars maker Hospira for US$17 billion. The products acquired in the deal will be integrated into Pfizer’s generics unit, Global Established Pharmaceutical (GEP).

Mylan on track to acquire Abbott generics and expand role in women’s health

Home/Pharma News | Posted 13/02/2015

The European Commission (EC) has approved Mylan’s acquisition of Abbott Laboratories' Non-US Developed Markets Specialty and Branded Generics Business (Abbott EPD-DM), subject to conditions. US-based generics manufacturer Mylan will have to sell off a number of its businesses in France, Germany, Ireland, Italy and UK in order to satisfy European Union merger regulations.

Actavis to buy UK generics maker Auden McKenzie

Home/Pharma News | Posted 06/02/2015

US generics maker Actavis announced on 26 January 2015 that it had agreed to buy UK generics maker Auden McKenzie. The deal will propel Actavis into the top position in the UK for generics suppliers, placing it in third position in the UK overall.

Amgen’s approach in the biosimilars market

Home/Pharma News | Posted 23/01/2015

Biotech giant Amgen now has a biosimilars programme that includes nine different molecules [1]. A representative from Amgen has spoken to GaBI about the company’s venture into biosimilars [2].

Cipla makes deal with Serum Institute for vaccines in Europe

Home/Pharma News | Posted 05/12/2014

India-based generics maker Cipla announced on 20 November 2014 that it had signed a deal with the Serum Institute of India (Serum Institute) to distribute vaccines in Europe.

Actavis buys Allergan and joins pharma top 10

Home/Pharma News | Posted 28/11/2014

On 17 November 2014, US generics maker Actavis announced that the company had made a deal to acquire botox-maker Allergan for US$66 billion.

Xbrane signs biosimilar optimization deal with Indian pharma firm

Home/Pharma News | Posted 14/11/2014

Swedish biotech company Xbrane Bioscience (Xbrane) has signed an agreement with a global Indian pharmaceutical company to assist them in developing an optimized production system for a specific biosimilar that will be marketed worldwide. The aim is to help the client reduce production costs in order to gain a competitive advantage in the biosimilar market.

Cipla Medpro to collaborate with Teva for generics in South Africa

Home/Pharma News | Posted 07/11/2014

India-based generics maker Cipla announced on 8 October 2014 that it had made a collaboration deal with Israel’s Teva Pharmaceuticals for sales and distribution of the latter’s generic drugs in South Africa.